KCT0006529招募中未知
A phase 2 study of stereotactic ablative radiotherapy(SBRT) followed by Atezolizumab / Tiragolumab in treatment-naive patients with metastatic non-small cell lung cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Age (at the time of informed consent): 20 years and older
- •2. Subjects with histologically- or cytologically-confirmed advanced or metastatic non-small cell lung cancer according to 8th edition clinical staging system of the American Joint Committee on Cancer before the start of concurrent chemoradiotherapy
- •3. ECOG Performance Status Score 0 or 1
- •4. Patient with no prior systemic treatment for advanced or metastatic NSCLC
- •5. PD-L1 expression 1%
- •6. Patients with a life expectancy of at least 3 months
- •7. Patients with measurable disease
- •8. Patients whose latest laboratory data meet the below criteria within 7 days before enrollment. If the date of the laboratory tests at the time of enrollment is not within 7 days before the first dose of the investigational product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days before testing.
- •White blood cells =2,000/mm3 and neutrophils =1,500/mm3
- •Platelets =100,000/mm3
- •Hemoglobin =9.0 g/dL
- •AST (GOT) and ALT (GPT) =3.0-fold the upper limit of normal (ULN) of the study site (or =5.0-fold the ULN of the study site in patients with liver metastases)
- •Total bilirubin =1.5-fold the ULN of the study site
- •Creatinine =1.5-fold the ULN of the study site or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) >45 mL/min
- •9. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons) #1 must agree to use contraception#2 from the time of informed consent until 5 months or more after the last dose of the investigational product, or until 12 months after SBRT completion, whichever is longer. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product, or until 12 months after SBRT completion, whichever is longer.
- •10. Men must agree to use contraception#2 from the start of study treatment until 7 months or more after the last dose of the investigational product, or until 12 months after SBRT completion, whichever is longer.
- •#1. Women of childbearing potential are defined as all women after the onset of menstruation who are not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Postmenopause is defined as amenorrhea for =12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.
- •#2. The subject must consent to use any two of the following methods of contraception: vasectomy or condom for patients who are male or female subject’s partner and tubal ligation, contraceptive diaphragm, intrauterine device, spermicide, or oral contraceptive for patients who are female or male subject’s partner.
排除标准
- •1. Patients with known driver oncogenes (EGFR, ALK, ROS1)
- •2. Multiple lesions that cause RT dose beyond normal organ dose constraints
- •3. Patients with only lesions such as pleural effusion, peritoneal seeding or leptomeningeal metastases that are not suitable for local RT
- •4. Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, thyroid cancer or any other cancer that has not recurred for at least 5 years)
- •5. Patients with current or past history of severe hypersensitivity to any other antibody products
- •6. Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease
- •7. Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be enrolled if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.
- •8. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease
- •9. Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment. Patients may be enrolled if the metastasis is asymptomatic and requires no treatment.
- •10. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment
- •11. Patients who have experienced a transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before enrollment
- •12. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:
- •? Myocardial infarction within 180 days before enrollment
- •? Uncontrollable angina pectoris within 180 days before enrollment
- •? New York Heart Association (NYHA) Class III or IV congestive heart failure
- •? Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure =150 mmHg or diastolic blood pressure = 90 mmHg lasting 24 hours or more)
- •? Arrhythmia requiring treatment
- •13. Patients with systemic infections requiring treatment
- •14. Patients who have received systemic corticosteroids (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before enrollment (exception with followings: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study)
- •15. Patients who have undergone surgery under general anesthesia within 28 days before enrollment
- •16. Patients who have received radiotherapy within 28 days before enrollment, or radiotherapy to bone metastases within 14 days before enrollment
- •17. Patients with a positive test result for any of the following: HBs antigen, or HCV antibody (except if HCV-RNA negative)
- •18. Patients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA
- •19. Women who are pregnant or breastfeeding, or possibly pregnant
- •20. Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before enrollment
- •21. Patients judged
研究者
相似试验
招募中
1 期
Phase I/II study of stereotactic radiotherapy for renal cell cancerJPRN-UMIN000004172niversity of Yamanashi30
已完成
2 期
Phase II study of stereotactic radiotherapy with volumetric modulated arc therapy for primary lung cancer located adjacent to organ at riskJPRN-UMIN000022856Department of Radiuation Oncology, Tohoku University Graduate School of Medicine15
尚未招募
不适用
Multicenter Phase II study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma =5 cmNeoplasmsKCT0000454Korea Institute of Radiological & Medical Sciences54
已完成
2 期
Phase II study of stereotactic radiosurgery with volumetric modulated arc therapy for small lung cancerJPRN-UMIN000022855Department of Radiuation Oncology, Tohoku University Graduate School of Medicine21
尚未招募
不适用
Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy (SUPER) trial.Pancreatic cancer tumoursACTRN12617001571369Royal Adelaide Hospital250